Related Experiment Video

Updated: Aug 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals

Mark Hirsch1, John O'donnell, Anders Olsson

  • 1AstraZeneca, Wilmslow, UK. Mark.Hirsch@astrazeneca.com

International Journal of Cardiology
|September 28, 2005
PubMed

Insights

Rosuvastatin 10 mg is more cost-effective than atorvastatin 10 mg for lowering low-density lipoprotein cholesterol (LDL-C) and achieving treatment goals. This statin therapy offers better efficacy and value for patients managing high cholesterol.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacoeconomics
  • Clinical Lipidology

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for coronary heart disease.
  • Achieving LDL-C treatment goals is crucial for cardiovascular risk reduction.
  • Newer statins like rosuvastatin offer potential for improved patient outcomes within budget constraints.

Purpose of the Study:

  • To conduct a cost-effectiveness analysis comparing rosuvastatin 10 mg and atorvastatin 10 mg.
  • To evaluate the efficacy in lowering LDL-C and achieving guideline-defined goals after 12 weeks.
  • To compare the cost per 1% LDL-C reduction and cost per patient achieving goal.

Main Methods:

  • Pooled analysis of data from three randomized clinical trials.
  • Efficacy assessed by percent LDL-C reduction and proportion of patients reaching target.
  • Cost-effectiveness calculated based on drug acquisition costs only.

Main Results:

  • Rosuvastatin 10 mg demonstrated a lower cost per 1% LDL-C reduction ($1.85 vs. $2.37).
  • Significantly lower costs were observed for rosuvastatin 10 mg to achieve European LDL-C goals ($130.18 vs. $242.44).
  • Costs to reach National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III goals were also lower with rosuvastatin ($115 vs. $163).

Conclusions:

  • Rosuvastatin 10 mg is more efficacious and cost-effective than atorvastatin 10 mg for LDL-C reduction.
  • Rosuvastatin facilitates achievement of LDL-C treatment targets more efficiently.
  • This finding supports rosuvastatin as a preferred option for lipid management in clinical practice.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...